Astria Accounts Payable vs Non Currrent Assets Other Analysis
ATXS Stock | USD 9.47 0.46 5.11% |
Astria Therapeutics financial indicator trend analysis is way more than just evaluating Astria Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Astria Therapeutics is a good investment. Please check the relationship between Astria Therapeutics Accounts Payable and its Non Currrent Assets Other accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Astria Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. For more information on how to buy Astria Stock please use our How to Invest in Astria Therapeutics guide.
Accounts Payable vs Non Currrent Assets Other
Accounts Payable vs Non Currrent Assets Other Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Astria Therapeutics Accounts Payable account and Non Currrent Assets Other. At this time, the significance of the direction appears to have almost no relationship.
The correlation between Astria Therapeutics' Accounts Payable and Non Currrent Assets Other is 0.17. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Non Currrent Assets Other in the same time period over historical financial statements of Astria Therapeutics, assuming nothing else is changed. The correlation between historical values of Astria Therapeutics' Accounts Payable and Non Currrent Assets Other is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Astria Therapeutics are associated (or correlated) with its Non Currrent Assets Other. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Currrent Assets Other has no effect on the direction of Accounts Payable i.e., Astria Therapeutics' Accounts Payable and Non Currrent Assets Other go up and down completely randomly.
Correlation Coefficient | 0.17 |
Relationship Direction | Positive |
Relationship Strength | Insignificant |
Accounts Payable
An accounting item on the balance sheet that represents Astria Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Astria Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Non Currrent Assets Other
Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.Most indicators from Astria Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Astria Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Astria Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. For more information on how to buy Astria Stock please use our How to Invest in Astria Therapeutics guide.Selling General Administrative is likely to drop to about 12.7 M in 2024. Issuance Of Capital Stock is likely to drop to about 82.6 M in 2024
Astria Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Astria Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Astria Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 41.8M | 47.5M | 127.5M | 230.6M | 254.7M | 267.4M | |
Other Current Liab | 2.6M | 4.2M | 3.3M | (788K) | 9.7M | 10.2M | |
Total Current Liabilities | 5.0M | 6.4M | 5.2M | 582K | 11.6M | 6.2M | |
Total Stockholder Equity | 35.7M | 40.7M | 122.3M | 221.2M | 243.1M | 255.3M | |
Property Plant And Equipment Net | 2.3M | 966K | 394K | 948K | 363K | 706.5K | |
Net Debt | (7.6M) | (23.9M) | (86.1M) | (19.6M) | (175.4M) | (166.6M) | |
Retained Earnings | (223.6M) | (260.9M) | (455.8M) | (507.6M) | (580.5M) | (551.5M) | |
Accounts Payable | 1.2M | 1.5M | 1.6M | 788K | 1.5M | 1.3M | |
Cash | 9.9M | 24.9M | 86.5M | 20.5M | 175.7M | 184.5M | |
Non Current Assets Total | 2.8M | 1.1M | 439K | 4.2M | 3.7M | 3.9M | |
Non Currrent Assets Other | 473K | 165K | 45K | 3.2M | 3.4M | 3.5M | |
Cash And Short Term Investments | 36.2M | 44.9M | 125.5M | 226.4M | 246.7M | 259.0M | |
Common Stock Shares Outstanding | 1.9M | 3.1M | 8.9M | 14.6M | 30.1M | 31.6M | |
Liabilities And Stockholders Equity | 41.8M | 47.5M | 127.5M | 230.6M | 254.7M | 267.4M | |
Non Current Liabilities Total | 56K | 1.0M | 397K | 1.9M | 8.8M | 0.0 | |
Other Current Assets | 2.7M | 1.4M | 1.6M | 1.3M | 4.2M | 4.5M | |
Other Stockholder Equity | 259.3M | 301.5M | 481.7M | 632.5M | 823.6M | 864.8M | |
Total Liab | 6.1M | 6.8M | 5.2M | 9.4M | 11.6M | 17.9M | |
Total Current Assets | 39.0M | 46.3M | 127.1M | 226.4M | 250.9M | 263.5M | |
Common Stock | 12K | 20K | 13K | 28K | 41K | 43.1K | |
Short Term Investments | 26.3M | 20M | 39M | 205.9M | 71M | 54.9M | |
Net Tangible Assets | 35.7M | 40.7M | 25.9M | 124.8M | 143.5M | 150.7M | |
Other Assets | 473K | 165K | 45K | 3.2M | 1.0 | 0.95 | |
Common Stock Total Equity | 7K | 12K | 20K | 28K | 32.2K | 20.0K | |
Net Invested Capital | 35.7M | 40.7M | 25.9M | 124.8M | 147.8M | 155.2M | |
Property Plant And Equipment Gross | 2.3M | 966K | 394K | 948K | 363K | 616.8K | |
Net Working Capital | 33.9M | 39.9M | 121.9M | 218.6M | 239.4M | 251.4M | |
Capital Stock | 12K | 20K | 96.4M | 96.4M | 95.4M | 52.8M |
Pair Trading with Astria Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Astria Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Astria Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Astria Stock
0.96 | EQ | Equillium | PairCorr |
Moving against Astria Stock
0.51 | VALN | Valneva SE ADR | PairCorr |
The ability to find closely correlated positions to Astria Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Astria Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Astria Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Astria Therapeutics to buy it.
The correlation of Astria Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Astria Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Astria Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Astria Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Astria Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. For more information on how to buy Astria Stock please use our How to Invest in Astria Therapeutics guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Complementary Tools for Astria Stock analysis
When running Astria Therapeutics' price analysis, check to measure Astria Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Astria Therapeutics is operating at the current time. Most of Astria Therapeutics' value examination focuses on studying past and present price action to predict the probability of Astria Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Astria Therapeutics' price. Additionally, you may evaluate how the addition of Astria Therapeutics to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
CEOs Directory Screen CEOs from public companies around the world | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |
Is Astria Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Astria Therapeutics. If investors know Astria will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Astria Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.40) | Return On Assets (0.16) | Return On Equity (0.28) |
The market value of Astria Therapeutics is measured differently than its book value, which is the value of Astria that is recorded on the company's balance sheet. Investors also form their own opinion of Astria Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Astria Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Astria Therapeutics' market value can be influenced by many factors that don't directly affect Astria Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Astria Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Astria Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Astria Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.